CD19 and neoplasm: Third, γδ T cells persist longer than CD28-costimulated CAR T cells, as was shown in a recent clinical trial, and have been found years after adoptive transfer in CD19 CAR T cell-treated patients [84], which could be relevant for persistent activity against tumor recurrence.